Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy

Journal of Medical Microbiology

Volumn 51, Issue 8, 2002, Pages 695-699

  Niesters, Hubert G M ^a   De Man, Robert A ^a   Pas, Suzan D ^a   Fries, Edwin ^a   Osterhaus, Albert D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; SERINE; TYROSINE; VALINE; VIRUS DNA;

ARTICLE; CASE REPORT; DNA DETERMINATION; GENE AMPLIFICATION; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN MOTIF; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS;

EID: 0036071201     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-51-8-695     Document Type: Article

References (26)

1. Lamivudine as initial treatment for chronic hepatitis B in the United States
2. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine
3. A one-year trial of lamivudine for chronic hepatitis B
4. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
5. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
6. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance
7. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
8. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy
9. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients
10. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
11. Hepatitis B reactivation after lamivudine
12. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
13. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays
14. A multicenter study evaluation of the Digene Hybrid Capture II signal amplification technique for detection of hepatitis B virus DNA in serum samples and testing of Eurohep standards
15. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations
16. Transmission of hepatitis B virus among heart transplant recipients during endomyocardial biopsy procedures
17. Molecular basis of hepatitis B virus serotype variations within the four major subtypes
18. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
19. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy
20. Hepatitis B virus antiviral drug resistance: From the laboratory to the patient
21. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro
22. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC)
23. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids
24. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome
25. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy
26. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine